MCID: PRS038
MIFTS: 68

Personality Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 30 15
Personality Disorders 56 44 74
Character Disorder 12
Personality 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 36 301.8 301.89
ICD10 34 F60 F60.9

Summaries for Personality Disorder

MedlinePlus : 44 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to avoidant personality disorder and schizoid personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Fluvoxamine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 77 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2267)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 34.5 MAOA SLC6A4 TPH1
2 schizoid personality disorder 34.4 HTR1A HTR2A
3 dependent personality disorder 33.8 DRD4 MAOA MAOB
4 intermittent explosive disorder 33.1 HTR1A PRL SLC6A4
5 antisocial personality disorder 32.4 ALDH2 ANKK1 COMT DRD2 HTR1B MAOA
6 borderline personality disorder 32.3 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
7 phobic disorder 31.8 COMT HTR1A MAOA SLC6A4
8 hypoactive sexual desire disorder 31.6 HTR1A HTR2A
9 exhibitionism 31.4 MAOA MAOB
10 phobia, specific 31.1 COMT MAOA
11 kleine-levin hibernation syndrome 30.9 COMT SLC6A3 TPH1
12 impulse control disorder 30.8 ANKK1 DRD2 DRD4
13 dysthymic disorder 30.7 HTR2A MAOA SLC6A4
14 agoraphobia 30.6 HTR1A MAOA SLC6A4
15 depression 30.6 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
16 social phobia 30.6 DRD2 HTR1A MAOA PRL SLC6A4
17 panic disorder 30.5 COMT HTR1A HTR2A MAOA SLC6A4
18 bulimia nervosa 30.3 BDNF COMT HTR1B HTR2A SLC6A4
19 conduct disorder 30.3 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
20 anorexia nervosa 30.2 BDNF COMT HTR2A PRL SLC6A4
21 cocaine dependence 30.2 DRD2 SLC6A3 SLC6A4
22 eating disorder 30.2 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
23 alexithymia 30.1 ANKK1 COMT DRD2 HTR1A SLC6A4
24 anxiety 30.1 BDNF COMT HTR1A HTR2A HTR2C MAOA
25 parkinson disease, late-onset 30.1 BDNF COMT DRD2 HTR1A HTR2A MAOA
26 chronic fatigue syndrome 30.0 COMT HTR1A HTR2A MAOA SLC6A4
27 brain injury 30.0 BDNF COMT DRD2
28 brunner syndrome 30.0 COMT HTR1A HTR1B MAOA MAOB SLC6A4
29 psychosexual disorder 30.0 HTR1A HTR2A HTR2C SLC6A4
30 fibromyalgia 30.0 COMT HTR2A PRL SLC6A4
31 kleptomania 30.0 HTR1A MAOA SLC6A4
32 traumatic brain injury 29.9 BDNF COMT DRD2
33 bipolar disorder 29.9 BDNF COMT DRD2 HTR1A HTR2A SLC6A3
34 opiate dependence 29.8 DRD2 SLC6A4 TPH1
35 sexual disorder 29.8 HTR1A PRL SLC6A4
36 postpartum depression 29.7 BDNF COMT MAOA PRL SLC6A4
37 drug dependence 29.7 ANKK1 BDNF DRD2 SLC6A4
38 tardive dyskinesia 29.7 COMT DRD2 HTR2A
39 atypical depressive disorder 29.7 HTR2A MAOA MAOB SLC6A4
40 schizophreniform disorder 29.7 COMT DRD2 PRL
41 paranoid schizophrenia 29.6 BDNF COMT HTR2A MAOA SLC6A4
42 bipolar i disorder 29.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
43 delusional disorder 29.5 DRD2 DRD4
44 mental depression 29.5 BDNF COMT HTR1A HTR2A HTR2C MAOA
45 schizoaffective disorder 29.5 BDNF COMT DRD2 HTR2A PRL SLC6A4
46 separation anxiety disorder 29.5 DRD4 PRL SLC6A3
47 endogenous depression 29.5 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
48 cocaine abuse 29.4 DRD2 PRL SLC6A3 SLC6A4
49 post-traumatic stress disorder 29.4 BDNF COMT DRD2 HTR2A MAOA MAOB
50 substance dependence 29.3 BDNF DRD2 DRD4 HTR1B MAOA SLC6A3

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.28 ALDH2 ANKK1 COMT DRD2 DRD4 HTR1A

MGI Mouse Phenotypes related to Personality Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
2 homeostasis/metabolism MP:0005376 10.1 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
3 cardiovascular system MP:0005385 10.02 ALDH2 AVPR1A COMT DRD2 HTR1A HTR1B
4 endocrine/exocrine gland MP:0005379 10.02 ALDH2 AVPR1A BDNF COMT DRD2 HTR1B
5 integument MP:0010771 9.76 ALDH2 BDNF DRD2 HTR2C PRL SLC6A3
6 muscle MP:0005369 9.61 ALDH2 AVPR1A DRD2 HTR1B HTR2A HTR2C
7 nervous system MP:0003631 9.44 ALDH2 AVPR1A BDNF COMT DRD2 DRD4

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
2
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
3
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
4
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
5
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54910-89-3 3386
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 61869-08-7 43815
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Not Applicable 79617-96-2 68617
8
Risperidone Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
10
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
11
Cycloserine Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-41-7 401 6234
12
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 303-49-1 2801
13
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
14
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
15
Guanfacine Approved, Investigational Phase 4,Phase 2,Not Applicable 29110-47-2 3519
16
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
17
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
18
Olanzapine Approved, Investigational Phase 4,Phase 3,Not Applicable 132539-06-1 4585
19
Haloperidol Approved Phase 4 52-86-8 3559
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
21
Propranolol Approved, Investigational Phase 4 525-66-6 4946
22
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
23
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
24
SB-649868 Experimental, Investigational Phase 4,Phase 3 110-16-7, 110-17-8 444972
25 Omega 3 Fatty Acid Phase 4,Phase 2,Phase 3,Not Applicable
26 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 calcium channel blockers Phase 4,Phase 2
40 Hormones Phase 4,Phase 1,Phase 2,Not Applicable
41 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Analgesics Phase 4,Phase 2,Phase 1,Not Applicable
44 Calcium, Dietary Phase 4,Phase 2
45 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
47 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
48 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 661)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Unknown status NCT00994786 Phase 4 pregabalin;Placebo
4 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
5 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Unknown status NCT00182520 Phase 4 Topiramate;placebo
6 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
7 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
8 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
9 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
10 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
11 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
12 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
13 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
14 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
15 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
16 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
17 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
18 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
19 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
20 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
21 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
22 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
23 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
24 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
25 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
26 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
27 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
28 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4 Anti-ADHD medication
29 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
30 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
31 Developing New Clinical Management Strategies Completed NCT02082392 Phase 4 Escitalopram
32 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
33 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
34 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
35 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
36 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
37 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
38 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
39 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
40 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
41 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
42 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
43 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
44 Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain Withdrawn NCT00227292 Phase 4 Escitalopram;Placebo
45 Safety and Effectiveness of Capsulotomy in Refractory OCD Unknown status NCT02375152 Phase 2, Phase 3
46 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder Unknown status NCT02590445 Phase 2, Phase 3
47 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
48 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
49 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
50 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 30

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

42
Brain, Testes, Cortex, Amygdala, Prefrontal Cortex, Eye, Pituitary

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 6991)
# Title Authors Year
1
Should childhood conduct disorder be necessary to diagnose antisocial personality disorder in adults? ( 30699216 )
2019
2
Evaluating dysfunction in cognition and reward among offenders with antisocial personality disorder. ( 30816777 )
2019
3
Post-traumatic stress disorder and having antisocial peers in adolescence are risk factors for the development of antisocial personality disorder. ( 30822743 )
2019
4
Single-Photon Emission Computed Tomography and Positron Emission Tomography Studies of Antisocial Personality Disorder and Aggression: a Targeted Review. ( 30852703 )
2019
5
Social anxiety disorder and avoidant personality disorder from an interpersonal perspective. ( 30656823 )
2019
6
Longitudinal associations among primary and secondary psychopathic traits, anxiety, and borderline personality disorder features across adolescence. ( 30628800 )
2019
7
Rejection Sensitivity and Borderline Personality Disorder Features: The Mediating Roles of Attachment Anxiety, Need to Belong, and Self-Criticism. ( 30650007 )
2019
8
Violent Offending in Borderline Personality Disorder and Attention Deficit/ Hyperactivity Disorder. ( 30844407 )
2019
9
Dimensions of Impulsivity in Healthy People, Patients with Borderline Personality Disorder, and Patients with Attention-Deficit/Hyperactivity Disorder. ( 30628513 )
2019
10
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
11
Struggling to be a person: Lived experience of avoidant personality disorder. ( 30609024 )
2019
12
Treating comorbid depression and avoidant personality disorder: The case of Andy. ( 30779449 )
2019
13
Common and distinct patterns of grey matter alterations in borderline personality disorder and bipolar disorder: voxel-based meta-analysis. ( 30846010 )
2019
14
Bipolar Disorder and Comorbid Borderline Personality Disorder: Patient Characteristics and Outcomes in US Hospitals. ( 30646620 )
2019
15
Screening for Borderline Personality Disorder in Psychiatric Outpatients With Major Depressive Disorder and Bipolar Disorder. ( 30677270 )
2019
16
Differentiating bipolar disorder from borderline personality disorder: Diagnostic accuracy of the difficulty in emotion regulation scale and personality inventory for DSM-5. ( 30699870 )
2019
17
Effect of negative valence on assessment of self-relevance in female patients with borderline personality disorder. ( 30629628 )
2019
18
Repetitive Transcranial Magnetic Stimulation in the Treatment of a Difficult to Treat Condition, Borderline Personality Disorder. ( 30633728 )
2019
19
Trustworthiness appraisal deficits in borderline personality disorder are associated with prefrontal cortex, not amygdala, impairment. ( 30639176 )
2019
20
Crying in borderline personality disorder patients. ( 30640050 )
2019
21
Longitudinal development of risk-taking and self-injurious behavior in association with late adolescent borderline personality disorder symptoms. ( 30641342 )
2019
22
The Role of Interactional Agreeableness in Responsive Treatments for Patients With Borderline Personality Disorder. ( 30650009 )
2019
23
Interdiagnostician Reliability of the DSM-5 Section II and Section III Alternative Model Criteria for Borderline Personality Disorder. ( 30650010 )
2019
24
The Relationship Among Shame, Nonsuicidal Self-Injury, and Suicidal Behaviors in Borderline Personality Disorder. ( 30654709 )
2019
25
Preliminary Validation of the Interpersonal Dysphoria Model of Borderline Personality Disorder. ( 30665228 )
2019
26
The role of attachment characteristics in dialectical behavior therapy for patients with borderline personality disorder. ( 30667573 )
2019
27
Changes in mindfulness facets in a dialectical behaviour therapy skills training group program for borderline personality disorder. ( 30672590 )
2019
28
Exploring the boundaries between borderline personality disorder and suicidal behavior disorder. ( 30673835 )
2019
29
Effects of transcranial direct current stimulation on the cognitive control of negative stimuli in borderline personality disorder. ( 30674987 )
2019
30
Collaborative Deprescribing in Borderline Personality Disorder: A Narrative Review. ( 30676404 )
2019
31
Impact of comorbid borderline personality disorder on inpatient treatment for bulimia nervosa: analysis of routine data. ( 30680217 )
2019
32
Influence of betrayal trauma on borderline personality disorder traits. ( 30681038 )
2019
33
Deaths by Suicide and Other Causes Among Patients With Borderline Personality Disorder and Personality-Disordered Comparison Subjects Over 24 Years of Prospective Follow-Up. ( 30688417 )
2019
34
Altered Oscillatory Responses to Feedback in Borderline Personality Disorder are Linked to Symptom Severity. ( 30689144 )
2019
35
Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: Protocol for the VERBATIM randomized controlled trial. ( 30689305 )
2019
36
Relations of Maternal Borderline Personality Disorder Features With Preschooler Executive Functioning and Theory of Mind. ( 30689501 )
2019
37
Women With Borderline Personality Disorder Show Reduced Identification of Emotional Facial Expressions and a Heightened Negativity Bias. ( 30689504 )
2019
38
Biased Attention to Facial Expressions of Ambiguous Emotions in Borderline Personality Disorder: An Eye-Tracking Study. ( 30689505 )
2019
39
The Therapeutic Alliance Over 10 Sessions of Therapy for Borderline Personality Disorder: Agreement and Congruence Analysis and Relation to Outcome. ( 30689513 )
2019
40
Mentalizing Based on External Features in Borderline Personality Disorder Compared With Healthy Controls: The Role of Attachment Dimensions and Childhood Trauma. ( 30689514 )
2019
41
Number of Borderline Personality Disorder Criteria and Depression Predict Poor Functioning and Quality of Life in Outpatient Youth. ( 30689518 )
2019
42
FKBP5 gene variants and borderline personality disorder. ( 30711865 )
2019
43
Hallucinations in patients with borderline personality disorder: characteristics, severity and relationship with schizotypy and loneliness. ( 30712290 )
2019
44
Metacognitive improvement and symptom change in a 3-month treatment for borderline personality disorder. ( 30712326 )
2019
45
Emotions at the border: Increased punishment behavior during fair interpersonal exchanges in borderline personality disorder. ( 30714797 )
2019
46
Optimizing borderline personality disorder treatment by incorporating significant others: A review and synthesis. ( 30714800 )
2019
47
Emotional Responsiveness in Borderline Personality Disorder: The Role of Basal Hyperarousal and Self-Reported Emotional Regulation. ( 30720601 )
2019
48
Neuropsychological findings in recent onset schizophrenia and borderline personality disorder: a comparison study. ( 30724326 )
2019
49
Parenting in Patients with Borderline Personality Disorder, Sequelae for the Offspring and Approaches to Treatment and Prevention. ( 30729325 )
2019
50
Borderline Personality Disorder Symptom Comorbidity Within a High Externalizing Sample: Relationship to the Internalizing-Externalizing Dimensional Structure of Psychopathology. ( 30730780 )
2019

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.88 COMT DRD2 DRD4 MAOA MAOB SLC6A3
3
Show member pathways
12.84 ALDH2 COMT MAOA SLC6A3 SLC6A4
4 12.19 BDNF DRD2 HTR1A HTR1B
6 12.06 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
7
Show member pathways
11.87 BDNF DRD2 MAOA MAOB SLC6A3
8
Show member pathways
11.78 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9
Show member pathways
11.75 ALDH2 MAOA MAOB TPH1
10
Show member pathways
11.64 COMT MAOA MAOB
11 11.62 HTR1A HTR1B HTR2A HTR2C MAOA MAOB
12
Show member pathways
11.48 ALDH2 MAOA MAOB
13
Show member pathways
11.32 MAOA SLC6A3 SLC6A4
14
Show member pathways
11.2 ALDH2 MAOA MAOB
15
Show member pathways
11 COMT MAOA TPH1
16
Show member pathways
10.97 ALDH2 COMT MAOA SLC6A3 SLC6A4
17 10.9 HTR2A HTR2C
18
Show member pathways
10.8 ALDH2 COMT MAOA MAOB
19 10.78 COMT MAOA MAOB
20
Show member pathways
10.72 ALDH2 MAOA MAOB
21 10.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2 axon GO:0030424 9.77 BDNF COMT DRD2 HTR2A SLC6A3
3 integral component of postsynaptic membrane GO:0099055 9.46 DRD2 HTR2A SLC6A3 SLC6A4
4 dopaminergic synapse GO:0098691 9.43 DRD2 SLC6A3
5 integral component of presynaptic membrane GO:0099056 9.35 DRD2 HTR1B HTR2A SLC6A3 SLC6A4
6 serotonergic synapse GO:0099154 9.32 HTR1B SLC6A4
7 dendrite GO:0030425 9.23 BDNF COMT DRD2 DRD4 HTR1A HTR1B
8 integral component of membrane GO:0016021 10.18 AVPR1A COMT DRD2 DRD4 HTR1A HTR1B

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.93 DRD4 HTR1A HTR1B HTR2A HTR2C
2 cellular calcium ion homeostasis GO:0006874 9.88 DRD4 HTR2A HTR2C
3 response to toxic substance GO:0009636 9.87 DRD2 MAOB SLC6A4
4 locomotory behavior GO:0007626 9.86 DRD2 HTR2C SLC6A3
5 memory GO:0007613 9.85 BDNF HTR2A SLC6A4
6 social behavior GO:0035176 9.82 AVPR1A DRD4 SLC6A4
7 positive regulation of fat cell differentiation GO:0045600 9.82 HTR2A HTR2C TPH1
8 regulation of synaptic vesicle exocytosis GO:2000300 9.81 DRD2 HTR1B HTR2A
9 release of sequestered calcium ion into cytosol GO:0051209 9.79 DRD2 HTR2A HTR2C
10 response to cocaine GO:0042220 9.78 DRD2 HTR1B SLC6A3
11 feeding behavior GO:0007631 9.75 DRD2 HTR1B HTR2C
12 behavioral fear response GO:0001662 9.74 DRD4 HTR1A HTR2C
13 activation of phospholipase C activity GO:0007202 9.73 AVPR1A BDNF HTR2A
14 arachidonic acid secretion GO:0050482 9.72 DRD2 DRD4
15 temperature homeostasis GO:0001659 9.72 DRD2 HTR2A
16 response to organic cyclic compound GO:0014070 9.72 COMT SLC6A3
17 positive regulation of kinase activity GO:0033674 9.72 DRD4 HTR2A
18 response to corticosterone GO:0051412 9.71 AVPR1A MAOB
19 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD4
20 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD4
21 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
22 bone remodeling GO:0046849 9.71 HTR1B TPH1
23 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
24 grooming behavior GO:0007625 9.7 AVPR1A DRD2
25 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
26 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD4 HTR2A
27 positive regulation of renal sodium excretion GO:0035815 9.69 AVPR1A DRD2
28 vasoconstriction GO:0042310 9.69 HTR1A HTR1B SLC6A4
29 G protein-coupled receptor internalization GO:0002031 9.68 DRD2 HTR1B
30 circadian rhythm GO:0007623 9.68 SLC6A4 TPH1
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD4
32 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
33 regulation of behavior GO:0050795 9.67 HTR1A HTR1B
34 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
35 dopamine metabolic process GO:0042417 9.67 COMT DRD2 DRD4
36 response to ethanol GO:0045471 9.67 DRD2 HTR1B MAOB SLC6A3
37 behavioral response to ethanol GO:0048149 9.66 DRD2 DRD4
38 monoamine transport GO:0015844 9.66 SLC6A3 SLC6A4
39 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD2 DRD4
40 drinking behavior GO:0042756 9.65 DRD2 HTR1B
41 neurotransmitter catabolic process GO:0042135 9.65 COMT MAOA MAOB
42 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 DRD4 HTR1A HTR1B HTR2A HTR2C
43 sperm ejaculation GO:0042713 9.63 AVPR1A SLC6A4
44 regulation of dopamine metabolic process GO:0042053 9.63 DRD4 HTR1A SLC6A3
45 negative regulation of serotonin secretion GO:0014063 9.62 HTR1B MAOB
46 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.62 HTR2A HTR2C
47 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 DRD4 HTR1A HTR1B HTR2A
48 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 DRD2 HTR1B HTR2A
49 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.6 HTR1A HTR1B
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.59 DRD2 DRD4

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2 neurotransmitter receptor activity GO:0030594 9.65 DRD4 HTR1A HTR1B HTR2A HTR2C
3 G protein-coupled serotonin receptor activity GO:0004993 9.55 DRD4 HTR1A HTR1B HTR2A HTR2C
4 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
5 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.48 SLC6A3 SLC6A4
8 primary amine oxidase activity GO:0008131 9.46 MAOA MAOB
9 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD2 DRD4
10 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
11 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.4 HTR2A HTR2C
12 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C SLC6A4

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....